Human Immunodeficiency Virus Type 1 (HIV-1) Infection - Pipeline Insight, 2024

Human Immunodeficiency Virus Type 1 (HIV-1) Infection - Pipeline Insight, 2024

DelveInsight’s, “Human Immunodeficiency Virus Type 1 (HIV-1) Infection – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Understanding

Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Overview

HIV-1 is the most common type of Human Immunodeficiency Virus. It attacks the body's immune system. The virus destroys CD4 cells. CD4 cells help the body to fight infections. HIV-1 can severely damage immune system and lead to Acquired Immune Deficiency Syndrome (AIDS). Infection with HIV type 1 (HIV-1) typically occurs across mucosal surfaces or by direct inoculation. The virus first encounters dendritic cells (DCs), which subsequently facilitate spread of HIV-1 to CD4+ T lymphocytes. Human Immunodeficiency virus 1 is transmitted in bodily fluids that include: blood, semen, vaginal and rectal fluids, breast milk.

""Human Immunodeficiency Virus Type 1 (HIV-1) Infection - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline landscape is provided which includes the disease overview and Human Immunodeficiency Virus Type 1 (HIV-1) Infection treatment guidelines. The assessment part of the report embraces, in depth Human Immunodeficiency Virus Type 1 (HIV-1) Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Human Immunodeficiency Virus Type 1 (HIV-1) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

● The companies and academics are working to assess challenges and seek opportunities that could influence Human Immunodeficiency Virus Type 1 (HIV-1) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Human Immunodeficiency Virus Type 1 (HIV-1) Infection.

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Emerging Drugs Chapters

This segment of the Human Immunodeficiency Virus Type 1 (HIV-1) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Emerging Drugs

● UB421: United BioPharma

UB-421 is an experimental HIV antibody, under development in phase III by United Biomedical, Inc. (UBI), headquartered in Hauppauge, New York, U.S. for use in the treatment of HIV infection. By blocking the CDR2 domain of the CD4 receptor of the virus, it prevents initial viral attachment to the host T cell and entry into the host immune cell via a competitive inhibition mechanism.

● Islatravir (MK-8591): Merck Sharp & Dohme

Islatravir belongs to a group of HIV drugs called nucleoside reverse transcriptase translocation inhibitors (NRTTIs). NRTTIs use several different methods to block an HIV enzyme called reverse transcriptase. By blocking reverse transcriptase, NRTTIs prevent HIV from multiplying and can reduce the amount of HIV in the body. Currently, it is being investigated in Phase III as a potential treatment for Hiv 1 infections.

● PRO140: CytoDyn Inc.

Leronlimab (Pro 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated in Phase II as a potential treatment for HIV1 infections.

Further product details are provided in the report……..

Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Therapeutic Assessment

This segment of the report provides insights about the different Human Immunodeficiency Virus Type 1 (HIV-1) Infection drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in Human Immunodeficiency Virus Type 1 (HIV-1) Infection

There are approx. 10+ key companies which are developing the therapies for Human Immunodeficiency Virus Type 1 (HIV-1) Infection. The companies which have their Human Immunodeficiency Virus Type 1 (HIV-1) Infection drug candidates in the most advanced stage, i.e. phase III include, United Biopharma.

● Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration

Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Intramuscular
• Subcutaneous

● Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Small molecule

● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Human Immunodeficiency Virus Type 1 (HIV-1) Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Human Immunodeficiency Virus Type 1 (HIV-1) Infection drugs.

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Report Insights

• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Human Immunodeficiency Virus Type 1 (HIV-1) Infection drugs?
• How many Human Immunodeficiency Virus Type 1 (HIV-1) Infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infection?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Human Immunodeficiency Virus Type 1 (HIV-1) Infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Human Immunodeficiency Virus Type 1 (HIV-1) Infection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• United BioPharma
• Gilead sciences
• Taimed Biologics
• Merck Sharp &Dohme
• Janssen Sciences
• CytoDyn Biosciences
• MacroGenics

Key Products

• UB421
• MK-8591A
• Ibalizumab
• Lamivudine